Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824758 | Clinical Therapeutics | 2015 | 11 Pages |
Abstract
Pharmacokinetics (AUC and Cmax) of canagliflozin increased in a dose-dependent manner after single oral doses of canagliflozin (100 and 300 mg) in these healthy Chinese subjects. Tmax and t½ of canagliflozin were independent of the dose. Canagliflozin decreased the 24-hour mean renal threshold for glucose and increased urinary glucose excretion in a dose-dependent manner; these results are consistent with those observed in other patient populations. Canagliflozin was generally safe and well tolerated in these healthy Chinese subjects. ClinicalTrials.gov identifier: NCT01707316.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Xia MD, Pei MD, Nicole BS, David PhD, Christopher R. BS, Hans MSc, Sue MD, PhD, Sveta MS, Damayanthi PhD,